|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases显示文摘Inflammatory bowel diseases (IBDs) such as Crohn's disease are highly debilitating. There are inconsistencies in response to and side effects in the current conventional medications, failures in adequate drug delivery, and the lack of therapeutics to offer complete remission in the presently available treatments of IBD. This suggests the need to explore beyond the horizons of conventional approaches in IBD therapeutics. This review examines the arena of the evolving IBD nanomedicine, studied so far in animal and in vitro models, before comprehensive clinical testing in humans. The investigations carried out so far in IBD models have provided substantial evidence of the nanotherapeutic approach as having the potential to overcome some of the current drawbacks to conventional IBD therapy. We analyze the pros and cons of nanotechnology in IBD therapies studied in different models, aimed at different targets and mechanisms of IBD pathogenesis, in an attempt to predict its possible impact in humans. | Madharasi VA Pichai Lynnette R Ferguson | 2012 | World Journal of Gastroenterology2012，18，23： | 19 |
| 2 | Residual renal function in peritoneal dialysis with failed allograft and minimum immunosuppression显示文摘Immunosuppression(IS) is often withdrawn in patients with end stage renal disease secondary to a failed renal allograft, and this can lead to an accelerated loss of residual renal function(RRF). As maintenance of RRF appears to provide a survival benefit to peritoneal dialysis(PD) patients, it is not clear whether this benefit of maintaining RRF in failed allograft patients returning to PD outweigh the risks of maintaining IS. A 49 year-old Caucasian male developed progressive allograft failure nine years after living-donor renal transplantation. Hemodialysis was initiated via tunneled dialysis catheter(TDC) and IS was gradually withdrawn. Two weeksafter IS withdrawal he developed a febrile illness, which necessitate removal of the TDC and conversion to PD. He was maintained on small dose of tacrolimus(1 mg/d) and prednisone(5 mg/d). Currently(1 year later) he is doing exceedingly well on cycler-assisted PD. Residual urine output ranges between 600-1200 m L/d. Total weekly Kt/V achieved 1.82. RRF remained well preserved in this patient with failed renal allograft with minimal immunosuppressive therapy. This strategy will need further study in well-defined cohorts of PD patients with failed allografts and residual RRF to determine efficacy and safety. | Nadear Elmahi éva Csongrádi Kenneth Kokko Jack R Lewin Jamie Davison Tibor Fülp | 2013 | World Journal of Transplantation2013，3，2： | 5 |
| 3 | Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy显示文摘AIM:To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn’s disease(CD)and ulcerative colitis(UC).METHODS:The data from 41 patients with CD and 22 patients with UC were assessed.Twenty-four CD patients received infliximab,and 17 received adalimumab.The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn’s disease in CD and with the Mayo endoscopic subscore in UC.RESULTS:Mucosal healing was achieved in 23 CD and7 UC patients.Biological therapy had to be restarted in78%of patients achieving complete mucosal healing with CD and in 100%of patients with UC.Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.CONCLUSION:Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped. | Klaudia Farkas Péter László Lakatos Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár | 2014 | World Journal of Gastroenterology2014，20，11： | 2 |
| 4 | 前蛋白转化酶枯草溶菌素9变异、低密度脂蛋白胆固醇与神经认知功能损害的关系显示文摘尽管之前的研究引发了对抑制前蛋白转化酶枯草溶菌素9(proprotein convertase subtilisin/kexintype9,PCSK9)造成神经认知功能损害事件的关注,但近期一个第3期随机试验并没有发现药物性PCSK9抑制与神经认知损害有关。 | 黄洁 叶鹏 Mefford MT Rosenson RS Cushman M Farkouh ME McClure LA Wadley VG Irvin MR Bittner VA Safford MM Somaratne R Monda KL Muntner P Levitan EB | 2017 | 中华高血压杂志2017，25，12： | 2 |
| 5 | Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiadtion therapy for clinically localized prostate cancer显示文摘 | D’Amico VA Whitington R Malkowicz SB | 1998 | JAMA1998，280，11： | 1 |
| 6 | Polo-like kinase-1 is a target of the DNA damage checkpoint显示文摘 | Smits VA Klompmaker R Arnaud L | 2000 | Nat Cell Biol2000，2，9： | 1 |
| 7 | Electrodynamic characteristics of coaxial-radial line slow-wave structure显示文摘 | Glushkov A R Mukhin S V Solntsev VA | 1993 | Journal of Communications Technology and Electronic1993，38，2： | 1 |
| 8 | 显示文摘 | Toscano J Vaβen R Gil A | 2006 | Surface and Coatings Technology2006，201，7： | 1 |
| 9 | Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis显示文摘 | MARIA VA VICTORINO R M | 1997 | Hepatology1997，26，3： | 1 |
| 10 | The hemi- pie giover mafterst roke measurement and recovery 显示文摘 | Wade DT Langton - Hewer R Wood VA | 1983 | J Neu- ro Neuyosurg Psychiourty1983，46，3： | 1 |
| 11 | Degradation ofα-lactalbumin andβ-lactoglobulin by actinidin显示文摘 | Lourdes Va'zquez-Lara Salvador R Tello-Sol's Lorena Go'mez-Ruiz | 2003 | Food Biotechnology2003，17，2： | 1 |
| 12 | Chronobiology of the hair follicle: hunting the 'hair cycle clock'显示文摘 | Paus R Muller-Rover S Botchkarev VA | 1999 | J Invest Dermatol Symp Proc1999，4，： | 1 |
| 13 | A plus-end-directed motor enzyme that moves antiparaIlel microtubules in vitro locali- zes t9 the interzone of mitotic spindles显示文摘 | Nislow C Lombillo VA Kuriyama R | 1992 | Nature1992，359，6395： | 1 |
| 14 | A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer 显示文摘 | Perez-Soler R Papadimitradopoulou VA | 2004 | Semin Oncol2004，31，11： | 1 |
| 15 | Elevated levels of P27, P21 and cyclinD1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients 显示文摘 | Reed W Fllrenes VA Holm R | 1999 | Virchows Arch1999，435，： | 1 |
| 16 | 查看详情显示文摘 | PonsJ Chernenko VA Santamarta R | | 0，，： | 1 |
| 17 | Domestic animals and epidemiology of visceral Leishmaniasis, Nepal 显示文摘 | Narayan RB Gert VA Suman R | 2010 | Emerg Infect Dis2010，16，2： | 1 |
| 18 | Nasal Glioma and Encephalocele:diagnosis and management显示文摘 | Rahbar R Resto VA Robson CD | 2003 | Laryngoscope2003，113，12： | 1 |
| 19 | Ultrasonic aspiration in the surgical treatment of intracranial tumors 显示文摘 | Zeme S Frego L Gunetti R | 1981 | J Neurosurg Sci1981，25，1： | 1 |
| 20 | Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer 显示文摘 | D'Amico VA Whittington R Malkowicz BS | 1998 | Jama1998，280，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员